利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

232 条记录 (耗时 0.035 秒)

    MODIFIED SINGLE VARIABLE DOMAIN ANTIBODIES WITH REDUCED BINDING TO ANTI-DRUG-ANTIBODIES
    51.
    发明公开
    MODIFIED SINGLE VARIABLE DOMAIN ANTIBODIES WITH REDUCED BINDING TO ANTI-DRUG-ANTIBODIES 审中-公开
    MODIFIZIERTE EINZEL VARIABLEDOMÄNEN抗扭剂麻省理工学院BINDUNG AN AN-MEDIKAMENTEN-ANTIKÖRPER

    公开(公告)号：EP2987806A2

    公开(公告)日：2016-02-24

    申请号：EP15180982.9

    申请日：2012-08-13

    申请人： Glaxo Group Limited

    发明人： ASHMAN, Claire ,  BIRCHLER, Mary ,  DE WILDT, Rudolf M.T. ,  HOLLAND, Claire ,  LEWIS, Alan Peter ,  MORLEY, Peter ,  SANDAL, Thomas ,  STEWARD, Michael

    IPC分类号： C07K16/00 ,  C07K16/22 ,  C07K16/28 ,  C07K16/42

    CPC分类号： C07K16/42 ,  C07K16/00 ,  C07K16/22 ,  C07K16/2878 ,  C07K2317/40 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/60 ,  C07K2317/64 ,  C07K2319/00

    摘要： The present invention relates to modified proteins and peptides that have reduced ability to bind to pre-existing antibodies. Such modified protein/peptide molecules can comprise C-terminal additions, extensions or tags and/or certain amino acid substitutions. Such modified molecules (including fusions and conjugates thereof) comprise proteins, peptides, antigen binding molecules, antibodies or antibody fragments such as single variable domains e.g. human immunoglobulin (antibody) single variable domains, and also single variable domains derived from non-human sources such as a llama or camel, e.g. a VHH including a Nanobody™ (described in e.g. WO 94/04678 and WO 95/04079 inter alia). The invention further relates to uses, formulations, compositions comprising such modified C-terminally extended and/or amino acid substituted molecules and also to methods of production and expression of these molecules.

    摘要翻译： 本发明涉及具有降低与先前存在的抗体结合的能力的修饰的蛋白质和肽。 这种修饰的蛋白质/肽分子可以包含C-末端添加，延伸或标签和/或某些氨基酸取代。 这样的修饰分子（包括其融合物及其缀合物）包含蛋白质，肽，抗原结合分子，抗体或抗体片段，例如单可变结构域，例如， 人免疫球蛋白（抗体）单可变结构域，以及衍生自非人来源的单可变结构域，例如美洲驼或骆驼，例如。 包括纳米抗体的VHH“（例如WO 94/04678和WO 95/04079等）。 本发明还涉及包含这种修饰的C-末端延伸和/或氨基酸取代的分子的用途，制剂，组合物，以及这些分子的生产和表达方法。

    TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
    55.
    发明公开
    TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS 有权
    法预测，检测和干扰的减少具有可变免疫球蛋白-EINZELDOMÄNEN蛋白ASPEZIFISCHER试验

    公开(公告)号：EP2723769A2

    公开(公告)日：2014-04-30

    申请号：EP12729968.3

    申请日：2012-06-25

    申请人： Ablynx N.V.

    发明人： BAUMEISTER, Judith ,  BOUCHE, Marie-Paule, Lucienne, Armanda ,  BOUTTON, Carlo ,  BUYSE, Marie-Ange ,  SNOECK, Veerle ,  STAELENS, Stephanie

    IPC分类号： C07K16/00 ,  G01N33/00 ,  C07K16/28 ,  C07K16/42

    CPC分类号： C07K16/00 ,  A61K2039/505 ,  C07K16/2875 ,  C07K16/42 ,  C07K2317/22 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/35 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/92 ,  G01N33/5306 ,  G01N33/54393 ,  G01N33/6857

    摘要： This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay). Such predictive assays could for example be used to test whether a given ISV could have a tendency to give rise to such protein interference and/or such a signal; to select ISV's that are not or less prone to such protein interference or giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an ISV will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an ISV so as to reduce its tendency to give rise to such protein interference or signal; - methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; - modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have nor or a low(er)/reduced tendency to give rise to such protein interference or such a signal.

    摘要翻译： 本发明提供，并且在某些具体的，但非限制性的方面涉及：测定并可以用来预测是否如上述给定的ISV会受到蛋白的干扰和/或产生在（非特异性）信号在寻求 测定法（：如实施例中在ADA免疫测定法）。 搜索预测分析可以用来测试实例给定的ISV可能具有产生搜索蛋白干扰和/或寻求的信号的趋势; 选择ISV的不属于或不容易搜索蛋白干扰或给予寻求一个信号; 将（完全或部分）降低的倾向以产生干扰搜索或搜索，以测定或试验也可用于测试信号是否某些修饰在ISV; 和/或作为在测定或测试没有可用于指导修改或ISV的改进，以便降低其倾向以产生搜索蛋白干扰或信号; - 方法用于修改和/或改进的ISV为以去除或减少他们的倾向产生蛋白干扰搜索或搜索的信号; - 修改也可以在ISV引入并消除或减少其倾向产生蛋白干扰搜索或搜索信号; ISV的已特别选定的（例如，使用中所述的测定法（S））到没有或低（更低）/趋势降低产生蛋白干扰搜索或搜索的信号; 修改和/或改进ISV的有，也没有或低（更低）/减少倾向产生蛋白干扰搜索或搜索的信号。

    FUSION PROTEIN
    57.
    发明公开
    FUSION PROTEIN 有权
    融合蛋白

    公开(公告)号：EP2698386A1

    公开(公告)日：2014-02-19

    申请号：EP12770896.4

    申请日：2012-04-02

    申请人： Nihon Pharmaceutical Co., Ltd.

    发明人： KOGURE, Takahisa ,  NAKAJIMA, Kenji ,  HOMMA, Masayuki

    IPC分类号： C07K19/00 ,  A61K38/00 ,  A61P37/06 ,  C07K14/47 ,  C07K16/18 ,  C12P21/02 ,  C12N15/09

    CPC分类号： C07K16/42 ,  A61K38/00 ,  C07K14/705 ,  C07K2319/00 ,  C07K2319/30

    摘要： The present invention provides a new fusion protein which can specifically suppress the autoantibodies, which can effectively prevent or treat the autoimmune disease of autoantibody type, and which can be expressed in an amount sufficient for industrial production.
    A fusion protein, characterized in that, a protein (X) containing a site recognized by autoantibodies which are a cause of the autoimmune disease of autoantibody type is connected to a protein (A) containing a fragment of the antibody heavy chain constant region which exhibits the antibody-dependent cellular cytotoxicity with a linker peptide (L) consisting of one or more amino acid (s), wherein the protein (X), the linker peptide (L) and the protein (A) are connected in this order by means of peptide bond from N terminal to C terminal.

    摘要翻译： 本发明提供了一种能特异性抑制自身抗体的新型融合蛋白，能够有效预防或治疗自身抗体型自身免疫性疾病，并且其表达量足以用于工业生产。 1。一种融合蛋白，其特征在于，含有被自身抗体型自身免疫病的原因的自身抗体识别的位点的蛋白质（X）与含有抗体重链恒定区片段的蛋白质（A）连接， 使用由一个或多个氨基酸组成的接头肽（L）的抗体依赖性细胞毒性，其中蛋白质（X），接头肽（L）和蛋白质（A）以此顺序通过手段连接 肽键从N末端到C末端。